Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 6/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.34 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.34 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ERN1 | O75460 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4845838 | 0.76 | PDE7A (0.55) | PDE7ASMN1; SMN2MAPTALDH1A1MEN1 | |
| SCHEMBL2881438 | 0.72 | TDP1 (0.39) | PDE7ASMN1; SMN2MAPTLMNAALDH1A1 | |
| SCHEMBL2889573 | 0.71 | PDE7A (0.54) | PDE7ASMN1; SMN2MEN1KMT2AL3MBTL1 | |
| SCHEMBL26423429 | 0.69 | TDP1 (0.46) | PDE7ASMN1; SMN2MAPTLMNAALDH1A1 | |
| SCHEMBL57882 | 0.66 | TSHR (0.40) | MAPTALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL29145557 | 0.66 | MAPT (0.32) | PDE7ASMN1; SMN2MAPTL3MBTL1TXNRD1 | |
| SCHEMBL247495 | 0.66 | PARP1 (0.41) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL6800906 | 0.65 | TDP1 (0.38) | MAPTALDH1A1MEN1KMT2AMAPK1 | |
| SCHEMBL58127 | 0.63 | HSD17B10 (0.54) | SMN1; SMN2MAPTALDH1A1L3MBTL1TDP1 | |
| SCHEMBL1028967 | 0.63 | TDP1 (0.50) | PDE7ASMN1; SMN2MAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | claimed |
| EP-1603858-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NeuroSearch A/S (DK) | 2005-12-14 | — | — | EP | claimed |
| WO-2004080377-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NEUROSEARCH A/S (DK) | 2004-09-23 | — | — | WO | claimed |
| US-7741352-B2 | KCNQ channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2010-06-22 | — | — | US | disclosed |
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | NEUROSEARCH A/S (DK) | 2006-08-03 | — | — | US | disclosed |
| EP-1603858-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NeuroSearch A/S (DK) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004080377-A2 | KCNQ CHANNEL MODULATING COMPOUNDS AND THEIR PHARMACEUTICAL USE | NEUROSEARCH A/S (DK) | 2004-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173058-A1 | Kcnq channel modulating compounds and their pharmaceutical use | KCNQ1, KCNQ2, KCNQ5 | PDE7A 1278/4885SMN1; SMN2 2692/4885MAPT 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.